Transposon Mutagenesis Reveals RBMS3 Silencing as a Promoter of Malignant Progression of BRAF(V600E)-Driven Lung Tumorigenesis

Mutationally activated BRAF is detected in approximately 7% of human lung adenocarcinomas, with BRAF(T1799A) serving as a predictive biomarker for treatment of patients with FDA-approved inhibitors of BRAF(V600E) oncoprotein signaling. In genetically engineered mouse (GEM) models, expression of BRAF...

Descripción completa

Detalles Bibliográficos
Autores principales: Vaishnavi, Aria, Juan, Joseph, Jacob, Maebh, Stehn, Christopher, Gardner, Eric E., Scherzer, Michael T., Schuman, Sophia, Van Veen, J. Edward, Murphy, Brandon, Hackett, Christopher S., Dupuy, Adam J., Chmura, Steven A., van der Weyden, Louise, Newberg, Justin Y., Liu, Annie, Mann, Karen, Rust, Alistair G., Weiss, William A., Kinsey, Conan G., Adams, David J., Grossmann, Allie, Mann, Michael B., McMahon, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Tumor Biology and Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664136/
https://www.ncbi.nlm.nih.gov/pubmed/36112789
http://dx.doi.org/10.1158/0008-5472.CAN-21-3214

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9664136/
https://www.ncbi.nlm.nih.gov/pubmed/36112789
http://dx.doi.org/10.1158/0008-5472.CAN-21-3214

Ejemplares similares